Advertisement

α2-Adrenoceptor Interaction with Opiate Receptors

  • N. Matussek
Conference paper

Abstract

Various neuroendocrinological studies with the clonidine (CLON; Table 1) and desmethylimipramine (DMI) growth hormone (GH) stimulation tests showed a blunted GH response in endogenous depressives and in patients with major affective disorders. According to preliminary studies, the blunted GH response to CLON seems to be a trait marker or vulnerability factor for endogenous depression. Since GH responses to CLON and DMI are α2-adrenoceptor mediated, some authors have discussed the possibility of an α2-adrenoceptor subsensitivity to be responsible for the blunted GH response in endogenous depressive patients (for review see Matussek 1988).

Keywords

Growth Hormone Depressive Patient Growth Hormone Response Opiate Receptor Opiate Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aghajanian GK (1985) The neurobiology of opiate withdrawal: receptors, second messengers, and ion channels. Pair Oaks Hospital Psychiatry Lett 3 (10): 57–60Google Scholar
  2. Boyer P, Schaub C, Pichot P (1982) Growth hormone response to Clonidine test in depressive states. Neuroendocrinol Lett 4: 178Google Scholar
  3. Bramnert M, Hökfelt B (1984) Partial blockade by naloxone of clonidine-induced increase in plasma growth hormone in hypertensive patients. J Clin Endocrinol Metab 58: 374–377PubMedCrossRefGoogle Scholar
  4. Catalano M, Bellodi L, Lucca A, Brambilla F (1984) Lithium and alpha-2-adrenergic receptors: effects of lithium ion on clonidine-induced growth hormone release. Neuroendocrinol Lett 6: 61–66Google Scholar
  5. CharneyDS, Henninger GR, Sternberg DE, Hafstadt KM, Giddings S, Landis H (1982) Adrenergic receptor sensitivity in depression. Effects of Clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 39: 290–294Google Scholar
  6. Checkley SA (1978) A new distinction between the euphoric and the antidepressant effects of methylamphetamine. Br J Psychiatry 133: 416–423PubMedCrossRefGoogle Scholar
  7. Checkley SA, Slade AP, Shur E (1981) Growth hormone and other responses to Clonidine in patients with endogenous depression. Br J Psychiatry 138: 51–55PubMedCrossRefGoogle Scholar
  8. Eriksson E, Eden S, Modigh K (1981) Importance of norepinephrine alpha-2-receptor activation for morphine-induced rat growth hormone secretion. Neuroendocrinology 33: 91–96PubMedCrossRefGoogle Scholar
  9. Höhe M, Valido G, Matussek N (1986) Growth hormone response to Clonidine in endogenous depressive patients: evidence for a trait marker in depression. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry 1985. Developments in psychiatry, vol 7. Proceedings of the 4th world congress of biological psychiatry. Elsevier, Amsterdam, pp 862–864Google Scholar
  10. Lechin F, van der Dijs B, Jakubowicz D, Camero R, Villa S, Lechin E, Gomez F (1985a) Effects of Clonidine on blood pressure, noradrenaline, Cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone subjects. Neuroendocrinology 40: 253–261Google Scholar
  11. Lechin F, van der Dijs B, Jakubowicz D, Camero RE, Villa S, Arochia L, Lechin E ( 1985 b) Effects of Clonidine on blood pressure, noradrenaline, Cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients. Neuroendocrinology 41: 156–162Google Scholar
  12. Matussek N (1988) Catecholamines and mood: neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Neuroendocrinology of mood. Springer, Berlin Heidelberg New York, pp 141–182 (Current topics in neuroendocrinology, vol 8 )Google Scholar
  13. Matussek N, Höhe M (1989) Investigations with the specific α-opiate receptor agonist fentanyl in depressive patients: growth hormone, prolactin, Cortisol, noradrenaline, and euphoric responses. Neuropsychobiology 21: 1–8Google Scholar
  14. Matussek N, Ackenheil M, Hippius H, Müller F, Schröder H-T, Schultes H, Wasilewski B (1980) Effect of Clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res 2: 25–36PubMedCrossRefGoogle Scholar
  15. Schmitz-Bremen H (1926) Die Opiumbehandlung bei Geisteskrankheiten insbesondere bei Melancholie, ihre Geschichte, ihr heutiger Stand und eigene Erfahrungen. Allg Z Psychiatrie 83: 92–113Google Scholar
  16. Siever LJ, Uhde TW, Insel TR, Roy BF, Murphy DL (1982) Growth hormone response to Clonidine unchanged by chronic chlorgyline treatment. Psychiatry Res 7: 139–144PubMedCrossRefGoogle Scholar
  17. Uhde TW, Vittone BJ, Siever LJ, KayeWH, Post RM (1986) Blunted growth hormone response to Clonidine in panic disorder patients. Biol Psychiatry 21: 1077–1081CrossRefGoogle Scholar
  18. Weber M (1987) Die “Opiumkur” in der Psychiatrie. Ein Beitrag zur Geschichte der Psychopharmakotherapie. Sudhoffs Arch 71: 31–61PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • N. Matussek
    • 1
  1. 1.Psychiatrische KlinikUniversität MünchenMünchen 2Germany

Personalised recommendations